From: HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya
Variable | N | Median (IQR) or n (%) |
---|---|---|
Duration since diagnosis of HIV (Months) | 360 | 107.0 (71.5, 132.0) |
 Range (Min. – Max.) |  | 1.0–181.0 |
Duration before ART initiation (Months) | 360 | 44.0 (4.5, 78.5) |
 Range (Min. – Max.) |  | 0.0–166.0 |
Duration of ART use (Months) | 360 | 88.0 (51.0, 122.5) |
 Range (Min. – Max.) |  | 1.0–141.0 |
Duration of current ART (Months) | 360 | 51.0 (17.0, 76.0) |
 Range (Min. – Max.) |  | 0.0–147.0 |
ART Line | ||
 First line (NRTI + NNRTI) | 360 | 286 (79.4%) |
 Second line (NRTI + PI) |  | 74 (20.6%) |
Others | ||
 Dapsone |  | 5 (1.4%) |
 Septrin | 359 | 353 (98.3%) |
 Septrin/Isoniazid |  | 1 (0.3%) |
Suppressed viral load (< 1000 copies/ml) | 358 | 303 (84.6%) |
Baseline CD4 cell count per mm3 | 304 | 243.0 (10.8.0, 399.0) |
 Range (Min. – Max.) |  | 1.0–1459.0 |
 < 200.0 |  | 122 (40.1%) |
 200.0–499.0 | 304 | 132 (43.4%) |
 ≥ 500.0 |  | 50 (16.4%) |
Current CD4 cell count per mm3 | 360 | 491.0 (336.5, 701.0) |
 Range (Min. – Max.) |  | 1.0–1845.0 |
 < 200.0 |  | 33 (9.2%) |
 200.0–499.0 | 360 | 153 (42.5%) |
 ≥ 500.0 |  | 174 (48.3%) |
WHO Clinical stage | ||
 Stage 1 |  | 122 (35.6%) |
 Stage 2 | 343 | 61 (17.8%) |
 Stage 3 |  | 132 (38.5%) |
 Stage 4 |  | 28 (8.2%) |